Vectura Group
Vectura Group plc (LSE: VEC) is a British pharmaceuticals business based in Chippenham, Wiltshire. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
 | |
| Type | Public (LSE: VEC) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | Chippenham, England |
Number of locations | 5 (2019) |
Key people | Bruno Angelici, Chairman Will Downie, (CEO) |
| Revenue | £178.0 million (2019)[1] |
| £(27.0) million (2019)[1] | |
| £(22.1) million (2019)[1] | |
Number of employees | 450 (2019) |
History
The company was formed in 1997 as a start-up pharmaceuticals business.[2] In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies.[2] In 2004 it was listed on the Alternative Investment Market.[2] In 2007 it acquired Innovata plc, another developer of pulmonary products,[3] and then moved onto the full list of the London Stock Exchange.[2] It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014.[4] On 10 June 2016 Vectura completed a merger with Skyepharma; the merged company will continue to be known as Vectura.[5]
Operations
The group is a developer of inhaled therapies for the treatment of respiratory diseases.[6]
References
- "Annual Report 2019" (PDF). Vectura Group. Retrieved 17 June 2020.
- "History". Vectura Group. Retrieved 3 August 2016.
- Vectura buys Innovata Guardian, 17 November 2006
- "UK's Vectura buys Activaero for £108 million". Pharma Times. 16 March 2014. Retrieved 20 June 2015.
- "Vectura and Skyepharma to merge in £441m deal". The Telegraph. 16 March 2016. Retrieved 11 June 2016.
- "Dr Karl Keegan to join Vectura Group". Manufacturing Chemist. Retrieved 20 June 2015.
External links
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.